Company profile
UK company 11732114, incorporated on 18 December 2018.
Homepage - CellRev
Cellularevolution Limited is a UK company with status active founded in 2018 based in Yorkshire and the Humber.
Company number 11732114
Reference milestones and recent Companies House filing stream events.
AM22 | Transaction MzUyOTE4ODE0NWFkaXF6a2N4 | Paper/PDF filed
Published 10 Jul 2026 01:21
Company registered at Companies House
There are a number of well-established and emerging commercial markets exploiting scientific advances in growing living cells to 'manufacture' new products, including pharmaceutical drugs, stem cells, gene therapies and cell-based meat. Companies working on these developments are addressing some of the major challenges facing the world over the coming decades, such as global hunger, global warming and pandemic threats. Many of these applications rely on the use of Adherent cells - cells requiring a solid surface on which to grow, such as the bottom of a culture flask. There are currently two challenges that are limiting the development of companies that need to grow adherent cells: • The use of animal-derived components - leading to the potential for contamination, high cost and batch-to-batch variability. There is currently insufficient availability of these products to meet demand. Their use is also not current Good Manufacturing Practice (cGMP) compliant and can be ethically controversial. • The limitations of traditional batch cell culture - resulting in batch bioprocessing techniques for the culture of adherent cells that cannot meet current demands, creating a significant bottleneck to the future commercial potential of companies that produce or use adherent cells. CellulaREvolution has been set up to commercialise on-going research by Professor Che Connon, Dr Martina Miotto and their colleagues within the Institute of Genetic Medicine at Newcastle University to address both of these challenges. The core technology is protected by know-how. This includes the preparation/formulation of coatings and a novel coating process. These products have taken three years to date to develop. The process behind the technology is non-trivial and it would not be obvious to someone skilled in the art to be able to replicate the technology. Further IP will be generated as the technology continues to mature and in co-development with customers.
received innovateUK funding supported the development of an ECR (Dr Miotto) who has gained experience in starting a business BioProcessUk poster award for potential new technology Employing 2 people
1 Feb 2024 to 31 Jul 2025
Healthcare costs, manufacturing inefficiencies and population growth contributed to a substantial increase in the number of individuals struggling with dangerous or chronic diseases. For instance, the IDF Diabetes Atlas (2021) reports that 10.5% of the adult population (20-79 years) has diabetes, with almost half unaware that they are living with the cond...
1 Jun 2020 to 31 Jan 2021
no public description
1 Nov 2019 to 31 Mar 2021
Red blood cells (RBCs) are currently harvested from donors and represent the most common form of cell-based therapy. There is an urgent need for RBCs for transfusion, and this demand is predicted to rise as the population continues to have longer life expectations. In light of this, there has been considerable research advancement to generate RBCs in vitr...
1 May 2019 to 31 Oct 2020
"There are a number of well-established and emerging commercial markets exploiting scientific advances in growing living cells to 'manufacture' new products, including pharmaceutical drugs, stem cells, gene therapies and cell-based meat. Companies working on these developments are addressing some of the major challenges facing the world over the coming de...
